Circulating endothelial cells in COVID-19
- PMID: 32491212
- PMCID: PMC7300913
- DOI: 10.1002/ajh.25881
Circulating endothelial cells in COVID-19
Conflict of interest statement
L.A. received advisory honoraria from Celgene, Gilead, Roche, Janssen‐Cilag, Verastem and research support from Gilead, all unrelated to this correspondence.
Figures
Comment on
-
Endothelial cell infection and endotheliitis in COVID-19.Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21. Lancet. 2020. PMID: 32325026 Free PMC article. No abstract available.
References
-
- Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid‐19. New England Journal of Medicine. 2020. 10.1056/nejmoa2015432. - DOI - PMC - PubMed
-
- Moussa MD, Santonocito C, Fagnoul D, et al. Evaluation of endothelial damage in sepsis‐related ARDS using circulating endothelial cells. Intensive Care Med. 2015;41:231‐238. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources